Showing results (241-250 of 408) with videos related to

Sort By:
Pageof 41
Blood Advances|September 28, 2022
Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosisSanjal H Desai, Raphael Mwangi, Wern Lynn Ng, et al.
Leukemia & Lymphoma|July 25, 2022
Insurance-based disparities impact survival outcomes in Waldenström macroglobulinemia within the United StatesKaran L Chohan, Jithma P Abeykoon, Stephen M Ansell, et al.
Seminars in Oncology|February 14, 2002
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphomaLeo I Gordon, Thomas E Witzig, Greg A Wiseman, et al.
Haematologica|June 16, 2018
Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangementsEllen D McPhail, Matthew J Maurer, William R Macon, et al.
Blood Cancer Journal|July 18, 2021
Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab eraArushi Khurana, Raphael Mwangi, Stephen M Ansell, et al.
Blood|March 19, 2011
Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1Lucy S Hodge, Anne J Novak, Deanna M Grote, et al.
American Journal of Hematology|October 14, 2024
Characteristics and outcomes of incidentally diagnosed diffuse large B-cell lymphoma and implications for cancer screeningSuheil Albert Atallah-Yunes, Matthew J Rees, Raphael Mwangi, et al.
American Journal of Hematology|December 6, 2018
Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018Alessia Castellino, Jose S Pulido, Patrick B Johnston, et al.
Leukemia & Lymphoma|October 27, 2006
The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphomaIvana N M Micallef, Ellen D Remstein, Stephen M Ansell, et al.
Blood|September 29, 2018
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphomaHan W Tun, Patrick B Johnston, Lisa M DeAngelis, et al.
Pageof 41